Rachel Elizabeth Haurwitz
| Rachel Elizabeth Haurwitz | |
|---|---|
 | |
| Umumiy maʼlumotlar | |
| Tavalludi |
20-may 1985 Ostin |
| Qardosh loyihalar | |
Rachel Haurwitz (1985-yil 20-may) — amerikalik biokimyogar va strukturaviy biolog. U Caribou Biosciences nomli genomni tahrirlash bilan shugʻullanadigan kompaniyaning hammuassisi, bosh ijrochi direktori va prezidenti hisoblanadi.
Iqtiboslar
[tahrirlash]Maktabning birinchi kursidanoq RNK molekulasi meni oʻziga rom etgan edi. Men doktorlik dissertatsiyamni Jennifer Doudna laboratoriyasida himoya qildim va u yerda CRISPR ustida ishlagan birinchi talaba boʻldim. Uning laboratoriyasida bajarilgan ishlar asosida yana ikki olim bilan birgalikda Caribou Biosciences kompaniyasiga asos soldik. Men ilm-fan orqali jamiyatga toʻgʻridan-toʻgʻri ta’sir koʻrsatish uchun akademik muhitdan sanoatga oʻtishni xohladim. Bugun Caribou’dagi maqsadimiz — CRISPR gen tahrirlash texnologiyasining imkoniyatlarini roʻyobga chiqarish va ogʻir kasalliklarga chalingan bemorlarga yordam beradigan yangi, tub burilish yasovchi hujayra terapiyalarini ishlab chiqishdir[1]. | |
Since my freshman year of high school, I have been intrigued by RNA. I conducted my Ph.D. research in Jennifer Doudna’s lab where I was the first student to work on CRISPR. Based on work that was done in her lab, we co-founded Caribou Biosciences with two other scientists. I wanted to transition from academia to industry to have a more direct impact through science on my community. Today at Caribou, our goal is to help realize the promise of CRISPR genome-editing technology and to develop new, potentially transformative cell therapies to help patients with devastating diseases. A role in industry provides me the opportunity to contribute to the development of new therapies for patients that could have a meaningful impact on their lives. |
Kompaniya hammuassisi boʻlish ajoyib imkoniyat deb oʻylagandim (va haq boʻlib chiqdim!). Caribou’ga asos solish tavakkalchilik edi. Biz mablagʻ toʻplay olamizmi, jamoa tuza olamizmi va yakunda muvaffaqiyatli tashkilot qura olamizmi — buni bilmasdik. Shunga qaramay, bu men oʻzimni baxtli his qilgan hayajonli chaqiriq edi. Kompaniya hammuassisi, ayniqsa, asoschi-prezident va bosh direktor sifatida men koʻplab iqtidorli hamkasblar bilan ishlash va Caribou’ni muhim marralarga yetaklash imkoniga ega boʻldim. Jumladan, ilk allogen hujayra terapiyamiz (CB-010) boʻyicha 1-bosqich klinik sinovlarida birinchi bemorga dori yuborilishiga va 350 million dollarlik muvaffaqiyatli IPO oʻtkazilishiga erishdik[1]. | |
I thought that being a company co-founder would be an amazing opportunity (and I was right!). Founding Caribou was risky. We did not know if we’d be able to raise money, hire a team, and ultimately build a successful organization. However, it was an exciting challenge I feel really lucky to have jumped into. As a company co-founder, and especially as the founding president and CEO, I’ve had the opportunity to work with many talented colleagues and lead Caribou to achieve some important milestones, including dosing the first patient in our phase 1 clinical trial for our first allogeneic cell therapy, CB-010, and completing a successful $350 million IPO. |